Andrew Keezer

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.

S. Treon, Z. Hunter, J. Castillo, 2020, Blood advances.

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

S. Treon, A. Roccaro, A. Sacco, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors

S. Treon, Z. Hunter, J. Castillo, 2019, Blood.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.

S. Treon, Z. Hunter, J. Castillo, 2019, Blood advances.

Prediagnostic White Blood Cell DNA Methylation and Risk of Breast Cancer in the Prostate Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort

R. Ziegler, K. Kelsey, C. Schairer, 2021, Cancer Epidemiology, Biomarkers & Prevention.

Deepening of response after completing rituximab‐containing therapy in patients with Waldenstrom macroglobulinemia

S. Treon, Z. Hunter, J. Castillo, 2019, American journal of hematology.

Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia

R. Advani, M. Davids, S. Treon, 2018, Clinical Lymphoma Myeloma and Leukemia.

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

N. Gray, Jinhua Wang, S. Treon, 2020, Blood Cancer Journal.

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

S. Treon, Z. Hunter, J. Castillo, 2019, British journal of haematology.